Irina Astafieva

This inventor holds 23 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Abbott Cardiovascular Systems, Inc., Forsight Vision4, Inc., Advanced Cardiovascular Systems, Inc.. Active years: 2006-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Irina Astafieva. Retrieved from https://idiyas.com/inventor/irina-astafieva

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 5)

% Patents Active = 26.1

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 313(Granted Patents)

Location History:

Palo Alto, CA (US) (2006 - 2018)
Menlo Park, CA (US) (2016 - 2020)

Company Filing History:

10 out of 1,196

Abbott Cardiovascular Systems, Inc.

patents

5 out of 50

Forsight Vision4, Inc.

patents

4 out of 1,523

Advanced Cardiovascular Systems, Inc.

Years Active: 2006-2020

Loading Chart...

Areas of Expertise:

Receptor Tyrosine Kinase Inhibitors

Sustained Drug Delivery

Apo A-I Mimetic Peptides

Lipid Therapy

Vascular Diseases

Controlled Release

Biobeneficial Polyurethanes

Peptidyl Prodrugs

Hydrophilic Coatings

Implantable Medical Devices

Therapeutic Agents

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10765677 - Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof (2020-09-08),

2. 10363255 - Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof (2019-07-30),

3. 9968603 - Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant (2018-05-15),

4. 9895369 - Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof (2018-02-20),

5. 9474756 - Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof (2016-10-25),

6. 9358268 - Lipid therapy (2016-06-07),

7. 8895056 - Regional delivery of therapeutic agents for the treatment of vascular diseases (2014-11-25),

8. 8870847 - Blood vessel permeability-enhancement for the treatment of vascular diseases (2014-10-28),

9. 8785382 - Lipid therapy (2014-07-22),

10. 8748394 - Apo A-I mimetic peptides and methods of treatment (2014-06-10),

11. 8735344 - Sustained release of APO A-I mimetic peptides and methods of treatment (2014-05-27),

12. 8703167 - Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug (2014-04-22),

13. 8658194 - Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same (2014-02-25),

14. 8383592 - Apo A-I mimetic peptides and methods of treatment (2013-02-26),

15. 8309112 - Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same (2012-11-13),

Title: The Inventor Spotlight: Irina Astafieva

Introduction:

Irina Astafieva, a prolific inventor based in Palo Alto, CA, has made significant contributions in the field of pharmaceutical formulations. With 23 patents to her name, Astafieva's innovative work has been instrumental in advancing the development of stable and soluble formulations of receptor tyrosine kinase inhibitors (TKI).

Latest Patents:

Among her latest patents is the groundbreaking work on stable and soluble formulations of TKIs, such as pazopanib. These formulations are designed for sustained delivery of the active agent to target sites, offering a novel approach to drug delivery in the treatment of various conditions. Additionally, Astafieva's patents cover methods for converting different polymorphic forms of TKIs, further enhancing the versatility and effectiveness of these pharmaceutical compounds.

Career Highlights:

Astafieva has a rich professional background, having worked with renowned companies like Abbott Cardiovascular Systems, Inc. and Forsight Vision4, Inc. Her expertise and dedication to innovation have been instrumental in driving advancements in pharmaceutical research and development. Astafieva's work exemplifies her commitment to pushing the boundaries of scientific discovery and improving patient outcomes.

Collaborations:

Throughout her career, Astafieva has collaborated with esteemed professionals in the field, including colleagues like Paul M Consigny and Stephen D Pacetti. These collaborations have not only enriched her research endeavors but have also led to the development of cutting-edge solutions in the pharmaceutical industry. Astafieva's ability to work effectively in team settings underscores her collaborative spirit and commitment to collective success.

Conclusion:

In conclusion, Irina Astafieva stands out as a visionary inventor whose contributions have significantly impacted pharmaceutical research and development. Her innovative work in formulating stable and soluble TKIs demonstrates a pioneering approach to drug delivery, with far-reaching implications for patient care. Astafieva's career highlights and collaborations attest to her expertise and collaborative prowess, making her a true trailblazer in the field of pharmaceutical innovations.

Profile summary based on public USPTO records.